Actively Recruiting
To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
Led by Korea University Anam Hospital · Updated on 2024-08-27
3958
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are: * major adverse cardiovascular events within 48 months of the trial duration * microvascular events within 48 months of the trial duration
CONDITIONS
Official Title
To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with type 2 diabetes diagnosed by American Diabetes Association criteria
- Age 19 years or older
- Non-HDL-C at least 100 mg/dL and triglycerides between 200 and 500 mg/dL while on moderate-intensity statins
- Presence of cardiovascular risk factors
You will not qualify if you...
- Pregnant or breastfeeding women
- Uncontrolled hyperglycemia with HbA1c over 12.0% despite anti-diabetic treatment
- History of myopathy or rhabdomyolysis
- Liver enzymes (AST/ALT) more than 3 times the upper limit of normal
- Clinical evidence of genetic disorders such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Korea University Anam Hospital
Seoul, South Korea
Actively Recruiting
Research Team
S
SIN-GON KIM
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here